Significant Interaction between Activated Charcoal and Antiretroviral Therapy Leading to Subtherapeutic Drug Concentrations,Virological Breakthrough and Development of Resistance
Free accessCase reportFirst published online July, 2013
Significant Interaction between Activated Charcoal and Antiretroviral Therapy Leading to Subtherapeutic Drug Concentrations,Virological Breakthrough and Development of Resistance
A 42-year-old, treatment-experienced woman, virologically suppressed on tenofovir/emtricitabine and boosted atazanavir, experienced virological breakthrough, drop in CD4+ T-cell count and undetectable drug concentrations. Adherence to treatment was confirmed, but repeat testing yielded similar results. After 2 months, the patient stated that she had been taking activated charcoal to manage gastrointestinal symptoms associated with her combination antiretroviral therapy, but she had recently discontinued the charcoal. Atazanavir concentrations were therapeutic but the patient's viral load rebounded and genotype testing revealed new reverse transcriptase mutations. The patient was changed to zidovudine, lamivudine, and boosted darunavir and achieved viral suppression. At 1 year follow-up, her viral load remained <40 copies/ml. According to the drug interaction probability scale, our patient experienced a probable drug interaction between activated charcoal and atazanavir/ritonavir leading to virological breakthrough and development of resistance.
References
1.
BoffitoM., JacksonA., AmaraA.Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother2011; 55: 4218–4223.
2.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Fed Regist2012; 1–239. (Updated 27 March 2012. Accessed 8 January 2013.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3.
LittlewoodR.A., VanableP.A.Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care2008; 20: 1002–1018.
4.
TsengA., FoisyM., HughesC.A.The role of the pharmacist in caring for patients with HIV/AIDS: clinical practice guidelines. Can J Hosp Pharm2012; 65: 125–145.
5.
van den Bout- van den BeukelC.J.P., KoopmansP.P., van der VenA.J.A.M.Possible drug metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev2006; 38: 477–514.
6.
WiegmanD-J, BrinkmanK., FranssenE.J.F.Interaction of gingko biloba with efavirenz. AIDS2009; 23: 1184–1185.
7.
PiscitelliS.C., BursteinA.H., ChaittD.Indinavir concentrations and St John's wort. Lancet2000; 355: 547–548.
8.
American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists.Position paper: single-dose activated charcoal. Clin Toxicol (Phila)2005; 43: 61–87.
9.
OlsonK.R.Activated charcoal for acute poisoning: one toxicologist's journey. J Med Toxicol2010; 6: 190–198.
10.
American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists.Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol1999; 37: 731–751.
11.
JürgensC., Groth HoegbergL.C., GraudalN.A.The effect of activated charcoal on drug exposure in healthy volunteers: a metaanalysis. Clin Pharmacol Ther2009; 85: 501–505.
12.
HornJ.R., HanstenP.D., ChanL.N.Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother2007; 41: 674–680.
